Holen Sie sich die Stockscreener-App
9.435
4.75%
-0.47
Handel nachbörslich:
10.21
0.775
+8.21%
Schlusskurs vom Vortag:
$9.905
Offen:
$10.2
24-Stunden-Volumen:
1.88M
Relative Volume:
2.85
Marktkapitalisierung:
$587.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-4.2886
EPS:
-2.2
Netto-Cashflow:
$-8.40M
1W Leistung:
-28.85%
1M Leistung:
-23.17%
6M Leistung:
-31.78%
1J Leistung:
+18.09%
1-Tages-Spanne:
$9.41
$10.20
1-Wochen-Bereich:
$9.41
$13.09
52-Wochen-Spanne:
$6.93
$30.96
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IMNM | 9.435 | 587.66M | 0 | -106.81M | -8.40M | -2.20 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - MarketBeat
Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World
T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com
Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada
Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat
Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat
Immunome price target lowered to $21 from $23 at Piper Sandler - TipRanks
Immunome, Inc. Reports Q3 2024 Financial Results - TipRanks
Immunome Inc (IMNM) Q3 2024 Earnings: Revenue Surpasses Estimates at $2.91M, GAAP EPS Misses at -$0.78 - GuruFocus.com
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunome Reports $47.1M Q3 Loss, Advances Cancer Pipeline with Strong Cash Position | IMNM Stock News - StockTitan
(IMNM) Technical Pivots with Risk Controls - Stock Traders Daily
Immunome earnings missed by $0.24, revenue topped estimates - Investing.com Canada
FMR LLC's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Gap Up – Still a Buy? - Defense World
Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN
Analyst Expectations For Immunome's Future - Benzinga
Immunome (NASDAQ:IMNM) Shares Gap UpTime to Buy? - MarketBeat
Immunome (NASDAQ:IMNM) Now Covered by Stephens - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Stake Reduced by Wealth Enhancement Advisory Services LLC - Defense World
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - The Bakersfield Californian
Immunome CEO to Present at Guggenheim's First Healthcare Innovation Conference | IMNM Stock News - StockTitan
Vanguard Group Inc's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com
Immunome (NASDAQ:IMNM) Trading Up 8.7%Time to Buy? - MarketBeat
Learn to Evaluate (IMNM) using the Charts - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average PT from Brokerages - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Immunome Advances with Strategic Asset Acquisition and Agreement - Yahoo Finance
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire
Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 15.2% in October - MarketBeat
Immunome's (IMNM) Outperform Rating Reiterated at Wedbush - MarketBeat
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - The Bakersfield Californian
IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan
Immunome (IMNM) Price Target Increased by 179.17% to 34.17 - MSN
Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Cubist Systematic Strategies LLC Decreases Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily
Financial Metrics Exploration: Understanding Immunome Inc (IMNM) Through Ratios - The Dwinnex
Sei Investments Co. Cuts Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
(IMNM) Investment Analysis and Advice - Stock Traders Daily
Insider Selling: Rosett Max, Immunome Inc [IMNM] Chief Financial Officer divested 14,380 shares - Knox Daily
Did Immunome Inc (IMNM) perform well in the last session? - US Post News
The Manufacturers Life Insurance Company Has $2.02 Million Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):